Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus OVRAL 28.
CONEXXENCE vs OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Ethinyl estradiol: terminal half-life 13-27 hours (mean ~17 hours); norgestrel: terminal half-life 11-45 hours (mean ~24 hours). Clinical context: steady-state reached within 5-7 days; accumulation minimal with daily dosing.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal: ~40% as metabolites; fecal: ~60% via biliary excretion, primarily as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive